DAM
AVTX icon

DLD Asset Management’s Avalo Therapeutics AVTX Stock Holding History

DLD Asset Management’s Portfolio AVTX Stock Details AVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-23,400
Closed -$297K – 386
2025
Q3 		$297K Buy
+23,400
New +$201K 0.02% 242

Other funds holding AVTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

DLD Asset Management's AVTX Position: Q4 2025 in Review

DLD Asset Management sold out of Avalo Therapeutics (AVTX) in Q4 2025, closing a stake of 75,000 shares — an estimated $1.27M sold.

DLD Asset Management first reported a position in AVTX in Q3 2025 and held it in 1 quarter. The position peaked at $953K in Q3 2025. 84 funds tracked by Wall St. Rank hold AVTX as of Q4 2025.

  • DLD Asset Management reported no remaining Avalo Therapeutics position as of Q4 2025 after selling out during the quarter.
  • DLD Asset Management sold 75,000 Avalo Therapeutics shares in Q4 2025, an estimated $1.27M.
  • DLD Asset Management first reported a position in Avalo Therapeutics in Q3 2025 and held it in 1 quarter.
  • DLD Asset Management's Avalo Therapeutics position peaked at $953K in Q3 2025.
  • 84 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q4 2025.

Based on DLD Asset Management's 13F filing for Q4 2025, filed 13 Feb 2026.